Detalhe da pesquisa
1.
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Cancer
; 129(14): 2169-2178, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37060201
2.
Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
Prostate
; 81(1): 50-57, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32986884
3.
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
Prostate
; 81(10): 683-693, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33956343
4.
Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer.
Value Health
; 24(12): 1737-1745, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838271
5.
Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
Prostate
; 80(16): 1429-1437, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32949185
6.
Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer.
Curr Opin Urol
; 30(1): 30-35, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31609776
7.
Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Ann Hematol
; 95(5): 809-16, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26878861
8.
Detection of PSMA expression on circulating tumor cells by blood-based liquid biopsy in prostate cancer.
J Circ Biomark
; 13: 1-6, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38415240
9.
Precision medicine for prostate cancer: An international perspective.
Urol Oncol
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38614920
10.
Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature.
Curr Oncol
; 30(1): 923-937, 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36661719
11.
Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment.
Am Soc Clin Oncol Educ Book
; 43: e390166, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37220335
12.
A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors.
Cancers (Basel)
; 15(9)2023 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37174019
13.
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.
Res Sq
; 2023 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36798177
14.
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.
Prostate Cancer Prostatic Dis
; 25(2): 314-319, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35145218
15.
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Prostate Cancer Prostatic Dis
; 25(2): 199-207, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108647
16.
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.
Prostate Cancer Prostatic Dis
; 25(4): 713-719, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35013522
17.
Accumulation of copy number alterations and clinical progression across advanced prostate cancer.
Genome Med
; 14(1): 102, 2022 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36059000
18.
NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
Mol Cancer Res
; 19(7): 1137-1145, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33863813
19.
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy.
Eur Urol Focus
; 7(5): 1130-1136, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33032968
20.
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.
Nat Cancer
; 2(4): 444-456, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33899001